KR102828449B1 - 신규 조성물 - Google Patents

신규 조성물 Download PDF

Info

Publication number
KR102828449B1
KR102828449B1 KR1020187026291A KR20187026291A KR102828449B1 KR 102828449 B1 KR102828449 B1 KR 102828449B1 KR 1020187026291 A KR1020187026291 A KR 1020187026291A KR 20187026291 A KR20187026291 A KR 20187026291A KR 102828449 B1 KR102828449 B1 KR 102828449B1
Authority
KR
South Korea
Prior art keywords
cellulose
active pharmaceutical
drug
pharmaceutical composition
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026291A
Other languages
English (en)
Korean (ko)
Other versions
KR20190005826A (ko
Inventor
알버트 미란얀
Original Assignee
알버트 미란얀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알버트 미란얀 filed Critical 알버트 미란얀
Publication of KR20190005826A publication Critical patent/KR20190005826A/ko
Application granted granted Critical
Publication of KR102828449B1 publication Critical patent/KR102828449B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187026291A 2016-02-12 2017-02-10 신규 조성물 Active KR102828449B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1602579.3 2016-02-12
GBGB1602579.3A GB201602579D0 (en) 2016-02-12 2016-02-12 New compositions
PCT/GB2017/050345 WO2017137762A1 (en) 2016-02-12 2017-02-10 New compositions

Publications (2)

Publication Number Publication Date
KR20190005826A KR20190005826A (ko) 2019-01-16
KR102828449B1 true KR102828449B1 (ko) 2025-07-01

Family

ID=55697649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026291A Active KR102828449B1 (ko) 2016-02-12 2017-02-10 신규 조성물

Country Status (8)

Country Link
US (1) US11278563B2 (enExample)
EP (1) EP3413873B1 (enExample)
JP (2) JP7046000B2 (enExample)
KR (1) KR102828449B1 (enExample)
AU (1) AU2017217331B2 (enExample)
ES (1) ES2971977T3 (enExample)
GB (1) GB201602579D0 (enExample)
WO (1) WO2017137762A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109738540A (zh) * 2019-01-28 2019-05-10 山东鲁抗舍里乐药业有限公司 一种非甾体抗炎药非罗考昔含量的测定方法
EP3804701A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung einer pharmazeutischen formulierung mit kristallinen und amorphen anteilen eines wirkstoffes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970424A (ja) 1995-07-04 1997-03-18 Takeda Chem Ind Ltd 粒剤の製造法
DK1163234T3 (da) 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
DK1663168T3 (da) * 2003-09-08 2009-06-08 Mcneil Ab Nikotinformuleringer og anvendelse deraf
CN101102753A (zh) 2004-12-09 2008-01-09 拉格纳·Ek 包含低结晶度纤维素的药物制剂
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP2135601A1 (en) 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics 461(1):74-81 (2013.11.26)

Also Published As

Publication number Publication date
EP3413873A1 (en) 2018-12-19
JP2022037240A (ja) 2022-03-08
KR20190005826A (ko) 2019-01-16
AU2017217331A1 (en) 2018-10-04
JP2019504866A (ja) 2019-02-21
JP7046000B2 (ja) 2022-04-01
EP3413873B1 (en) 2023-12-27
US11278563B2 (en) 2022-03-22
US20190038661A1 (en) 2019-02-07
AU2017217331B2 (en) 2022-08-11
ES2971977T3 (es) 2024-06-10
EP3413873C0 (en) 2023-12-27
WO2017137762A1 (en) 2017-08-17
GB201602579D0 (en) 2016-03-30
CA3014618A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
TWI715291B (zh) 包含parp抑制劑的藥物組合物
EA014443B1 (ru) Фармацевтическая композиция (варианты) и способ ее производства
RS61466B1 (sr) Sastavi protiv raka
TW201526921A (zh) 一種替格瑞洛固體分散體及其製備方法
JP2022037240A (ja) 新規組成物
CN104016918A (zh) 石杉碱甲多晶型体、其制备方法、包含所述多晶型体的药物组合物及其用途
CN113260359A (zh) 酒精解毒剂
Sokal et al. Pharmaceutical cocrystals as an opportunity to modify drug properties: from the idea to application: a review
WO2015001133A1 (en) Pharmaceutical composition comprising amorphous ivabradine
KR102383617B1 (ko) 15β-하이드록시-아세트산오사테론의 결정 다형
PT2165702E (pt) Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
Bajpai et al. Design and in vitro evaluation of compression-coated pulsatile release tablets of losartan potassium
WO2017216584A1 (en) New compositions
Wardhana et al. In vitro solubility and release profile correlation with pka value of efavirenz polymorphs
WO2019081749A1 (en) IMMEDIATE RELEASE FORMULATIONS OF LENALIDOMIDE
CA3014618C (en) Pharmaceutical composition comprising cellulose and an active ingredient
RU2698703C2 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
EP3233082B1 (en) Pharmaceutical composition comprising amorphous lenalidomide
Al-Sarraf et al. Dissolution enhancement of telmisartan by liquisolid compacts
PT1928425E (pt) Formulação farmacêutica contendo um inibidor de hmg-coa redutase e método para a preparação deste
CN111419818A (zh) 包含呋喃酮的药物组合物以及包含该药物组合物的胶囊制剂
Hangargekar et al. FORMULATION AND IN-VITRO EVALUATION OF BILAYER TABLET CONTAININGZOLMITRIPTAN AND NAPROXEN
Nijhawan et al. Posaconazole-glutaric acid cocrystal tablet with improved Dissolution rate
EP3079702B1 (en) Pharmaceutical composition comprising amorphous ivabradine
KR20110115607A (ko) 6-옥소-6,7,8,9,10,11-헥사히드로시클로헵타(ｃ)크로멘-3-일 술파메이트 및 그의 다형체를 함유하는 고체 제약 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220207

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240817

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250408

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250627

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250627

End annual number: 3

Start annual number: 1

PG1601 Publication of registration